Table 2.
Baseline characteristics of the enrolled participants.
| Variable | HCC group (n = 133) | CHB group (n = 164) | HC group (n = 26) |
|---|---|---|---|
| Age (years) | 56 (51-62) | 49 (40-56) | 48.5 (35.75-55) |
| Male, n (%) | 106 (79.7) | 119 (72.6) | 11 (42.3) |
| ALT (U/L) | 38 (22.00-72.50) | 36.85 (25.00-90.75) | 24.50 (15.00-32.00) |
| AST (U/L) | 44 (31.00-107.00) | 47.00 (32.00-87.00) | 31.50 (22.50-38.25) |
| TBIL (μmol/L) | 22.10 (14.30-39.75) | 25.40 (14.55-57.45) | 9.00 (8.00-15.00) |
| ALB (g/L) | 39.00 (34.05-43.70) | 36.10 (31.40-41.38) | 49.50 (46.75-52.25) |
| PT-INR | 1.19 (1.11-1.29) | 1.28 (1.14-1.58) | NA |
| PTA (%) | 77 (67-84) | 68.5 (53-82.5) | NA |
| AFP (ng/ml) | 74.70 (4.62-800.00) | 6.94 (2.68-33.52) | NA |
| HBV-DNA (+), n (%) | 72 (54.1) | 122 (74.4) | NA |
| HBeAg (+), n (%) | 72 (54.1) | 102 (62.2) | NA |
| Encephalopathy (%) | 10 (7.5) | 17 (10.3) | NA |
| Ascites (%) | 47 (35.3) | 21 (12.8) | NA |
Quantitative variables are expressed as the median (centile 25; centile 75). Categorical variables are expressed as numbers (%). HCC, hepatocellular carcinoma; CHB, chronic hepatitis B; HC, healthy control; HBV, hepatitis B virus; AFP, alpha-fetoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALB, albumin; TBIL, total bilirubin; INR, international normalized ratio; PTA, prothrombin time activity; HBeAg, hepatitis B e surface antigen; NA, not available.